Guoqian Venture Capital
Guoqian Venture Capital Management (Suzhou) Co., Ltd. (hereinafter referred to as Guoqian Venture Capital) was established on March 3, 2017, and the first private equity fund was established in July 2017-Suzhou Guoqian Medical Venture Capital Enterprise (Limited Partnership) ).
Guoqian Venture Capital is composed of six specially appointed "Thousand Talents" experts from the Central Organization Department with successful entrepreneurship or industrial experience in various segments of medical devices, including Dr. Zhang Xu, the Suzhou Institute of Medical Engineering, Chinese Academy of Sciences, and investment and finance Experts jointly initiated the establishment of professional equity investment institutions, focusing on investment in medical devices (including in vitro diagnostic reagents), VC and PE in the field of medical services. Guoqian Venture Capital has a large team of thousands of expert consultants who can judge project technology, industry, industry, policy and development trends.

2018 is undoubtedly a turbulent year for the financial industry. The global financial market has experienced greater volatility.
In just two years, Guoqian Venture Capital has invested in six projects, including projects led by experts from the national "Thousand Talents Program" and university professors. They have made efforts in their respective medical devices and medical services. With contribution.
01
January
Aishi Medical Technology Chengdu Co., Ltd.

"Xiaoaiyan Butler" Chengdu Experience Store Opened

Conducted eye health class in Chengdu Experimental Primary School and conducted eye health examination for teachers and students
February

Aishi Medical Technology Chengdu Co., Ltd. 2018 Annual Meeting
June

Eye exam for teachers and students of Jiaxiang Foreign Language School, Chengdu Seventh Middle School
October

Presented at the China Science and Technology Association Double Innovation Week
November

Participated in the "Chengdu New Economic Development-Hong Kong Special Cooperation Promotion Conference" as a Chengdu enterprise delegation
02
July
Suzhou Xinqing Medical Technology Co., Ltd.

Professor Xu Boling was approved as "the first batch of Gusu entrepreneurial innovation leaders in 2018"
September

Officially entered Jiangsu Medical Device Industrial Park
October

Founder Professor Xu Boling hosted the 1st Mechanical Circulation Auxiliary Forum
December

Completed the development of engineering prototype and completed the first animal experiment

Approved the 2018 Jiangsu Policy Guidance Plan (International Technology Cooperation) Project
03
March
Suzhou Ruiqian Medical Technology Co., Ltd.

Completed the development of engineering prototype and realized high-speed, high-quality image scanning
June

Complete the development of seamless stitching software for pathological images
July
Completed the development of software system for pathology annotation and virtual panoramic pathology image preview
September

Dr. Wu Xiangchen was approved as "Jiangsu Province High-level Innovation and Entrepreneurship Talent Introduction Plan"
October
Complete the first round of financing
November
Approved as "Jiangsu Private Technology Enterprise"
December
Completed the construction of a cytopathology interpretation AI process framework containing standard tools such as data, training, and visualization
04
January
Nanjing Spectrum Life Biotechnology Co., Ltd.
Reached a strategic cooperation agreement with Shenzhen BGI Research Institute
April
Completed Pre-A round of financing
July



Completion of the second phase of the laboratory
December


Successfully synthesized IBT-15plex reagent and entered the test stage
05
July
Shenzhen Huanuo Biological Technology Co., Ltd.
"Shenzhen Ruibosi Regenerative Medicine Technology Co., Ltd." was renamed to "Shenzhen Huanuo Biotechnology Co., Ltd.
Complete angel round financing
September

Won the first prize of the "Fifth Shenzhen Baoan Innovation and Entrepreneurship Competition" in the enterprise group and the most favored award by investment institutions
December



Built nearly 10,000 square meters of clean production workshop

Mass production of hemostatic gel products
06
January
Qingpu (Shanghai) Analytical Instruments Co., Ltd.
Selected as a supporting enterprise in the "G60 Science and Technology Corridor
April

The independently developed Mini β small-scale mass spectrometry analysis system was awarded "2017 New Products of Scientific Instrument Industry"
May

MS Mate product line expansion
July
Completed Pre-A round of financing
September
Mini β mass spectrometry system successfully transferred to production
October
Completed Series A financing
November

Cooperating with Tsinghua University and Huashan Hospital, the first small-scale mass spectrometer is used for the development of human tissue clinical detection (POCT)
December

Nature Communications Announces Unsaturated Lipid Isomer Analysis Method, Establishes a New Biomarker Discovery Platform with Qingpu Technology Omega Reactor as the Core Module

Cooperated with Tsinghua University to develop a small mass spectrometer with a dual-line ion trap (LIT) structure, and published an Analytical Chemistry cover article
Xiongguan Mandao is really like iron,
Now this is a step forward.
This is an era of dreams,
The new year has arrived,
2019 carries more hope!
Let us work together to embark on the journey of the New Year!